Overview
Molecular Targeting Technologies, Inc., a West Chester, PA-based clinical-stage radiopharmaceutical company, has been awarded a $3.17m, five-year National Cancer Institute (NCI) grant. The company will advance the development of ¹⁷⁷Lu-EBRGD, an investigational radiopharmaceutical targeting integrin αvβ3, for non-small cell lung cancer (NSCLC)....See more
Website
https://www.mtarget.com/Headquarters
West Chester, PA
Upgrade to view team
View current team members and their roles
Access founders information
Request warm introductions
Funding Rounds (1)
$3.2M • Grant
Announced on 9/22/2026
Open Positions(0)
No open jobs posted for this organization yet.
Company Updates
No updates available yet.